NPS R-568 Norcalcin update

NPSP reported positive results from two studies of Norcalcin in HPT.

In a Phase I, placebo controlled, dose escalation study in 48 healthy patients over the age of 40, daily oral doses of 20-400 mg were administered for one week to assess safety, tolerance, pharmacokinetics and changes in serum calcitonin and markers of primary HPT (plasma concentrations of parathyroid hormone and ionized calcium). ...